PURPOSE: To evaluate the feasibility and complications of ultrasound (US)-guided biopsy of small renal masses (SRMs) and to determine factors that contribute to nondiagnostic biopsy specimens. MATERIALS AND METHODS: Between June 2004 and May 2011, 58 consecutive patients underwent US-guided core biopsy of a SRM (>1 cm and ≤4 cm) using an 18-gauge core biopsy device. The diagnostic rate, histologic diagnosis, and complications of US-guided core biopsy were assessed. Mann-Whitney U and Fisher exact tests were used to compare diagnostic and nondiagnostic biopsy specimens. Univariate analysis was performed to determine the predictive factors for nondiagnostic biopsy specimens. RESULTS: There were 59 biopsies of SRMs performed, and the diagnostic rate was 81% (48 of 59). The mass size of diagnostic and nondiagnostic biopsy specimens ranged from 1.2-3.9 cm (2.4 cm±0.7) for diagnostic specimens and from 1.1-3.5 cm (1.9 cm±0.7) for nondiagnostic specimens (P = .024). Of the diagnostic biopsy specimens, 77% (37 of 48) were malignant, and 23% (11 of 48) were benign. Minor complications developed in 20.3% (12 of 59) of biopsies. The lesion size or core number threshold for decreasing diagnostic rate was 2 cm or three cores. A cystic mass, fewer cores (three or fewer cores), an upper pole mass, and a small mass (≤2 cm) significantly predicted a nondiagnostic biopsy specimen (P = .007-.046). CONCLUSIONS: US-guided core biopsy is a feasible and safe procedure for histologic diagnosis of a SRM. However, nondiagnostic rates may increase when a cystic mass is biopsied, a mass is located in an upper pole mass, a mass is 2 cm or less, and three cores or fewer are sampled.
PURPOSE: To evaluate the feasibility and complications of ultrasound (US)-guided biopsy of small renal masses (SRMs) and to determine factors that contribute to nondiagnostic biopsy specimens. MATERIALS AND METHODS: Between June 2004 and May 2011, 58 consecutive patients underwent US-guided core biopsy of a SRM (>1 cm and ≤4 cm) using an 18-gauge core biopsy device. The diagnostic rate, histologic diagnosis, and complications of US-guided core biopsy were assessed. Mann-Whitney U and Fisher exact tests were used to compare diagnostic and nondiagnostic biopsy specimens. Univariate analysis was performed to determine the predictive factors for nondiagnostic biopsy specimens. RESULTS: There were 59 biopsies of SRMs performed, and the diagnostic rate was 81% (48 of 59). The mass size of diagnostic and nondiagnostic biopsy specimens ranged from 1.2-3.9 cm (2.4 cm±0.7) for diagnostic specimens and from 1.1-3.5 cm (1.9 cm±0.7) for nondiagnostic specimens (P = .024). Of the diagnostic biopsy specimens, 77% (37 of 48) were malignant, and 23% (11 of 48) were benign. Minor complications developed in 20.3% (12 of 59) of biopsies. The lesion size or core number threshold for decreasing diagnostic rate was 2 cm or three cores. A cystic mass, fewer cores (three or fewer cores), an upper pole mass, and a small mass (≤2 cm) significantly predicted a nondiagnostic biopsy specimen (P = .007-.046). CONCLUSIONS: US-guided core biopsy is a feasible and safe procedure for histologic diagnosis of a SRM. However, nondiagnostic rates may increase when a cystic mass is biopsied, a mass is located in an upper pole mass, a mass is 2 cm or less, and three cores or fewer are sampled.
Authors: Hiten D Patel; Michael H Johnson; Phillip M Pierorazio; Stephen M Sozio; Ritu Sharma; Emmanuel Iyoha; Eric B Bass; Mohamad E Allaf Journal: J Urol Date: 2016-02-18 Impact factor: 7.450
Authors: Connie Y Chang; Ambrose J Huang; Miriam A Bredella; Martin Torriani; Elkan F Halpern; Daniel I Rosenthal; Dempsey S Springfield Journal: Skeletal Radiol Date: 2015-09-04 Impact factor: 2.199
Authors: Selma Masic; Marshall Strother; Laura C Kidd; Brian Egleston; Avery Braun; Abhishek Srivastava; Marc Smaldone; Barton Milestone; Rosaleen Parsons; Rosalia Viterbo; Richard Greenberg; David Chen; Alexander Kutikov; Robert Uzzo Journal: Urology Date: 2021-08-08 Impact factor: 2.633